Search Result for : Sun Pharma

The Dollar Business Bureau On February 21, 2017, Indian Ambassador to Egypt Sanjay Bhattacharyya, inaugurated Sun Pharma’s manufacturing unit in 6th of October City in Cairo. Sun Pharma is an Indian multinational pharmaceutical company headquartered at Mumbai. The company manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulations in India and the US. Sun offers formulations in various therapeutic areas such as psychiatry, cardiology, neurology, diabetology, and gastroenterology. Sun Pharma is known for offering a wide range of healthcare products and medicines such as capsules, tablets, injectable, ointments, inhalers, creams, liquids and other dosages at affordable prices. The company has gained trust among healthcare professionals and patients across the globe. The third largest producer of pharmaceuticals in the world has started ...

The Dollar Business Bureau  Sun Pharma on Friday announced it has invested $13 million (about Rs.88 crore) in the US-based scPharmaceuticals Inc. "...One of the wholly-owned subsidiaries of the company has acquired 13,000,000 Series B preferred stock of scPharmaceuticals Inc (equivalent to 14.58% fully diluted equity stake on conversion) by way of allotment," Sun Pharmaceutical Industries said in a statement.  "Consideration for Series B preferred stock acquired is $13 million," it said. scPharmaceuticals Inc is a United States-based pharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery.   On Thursday, Sun Pharma announced it was planning to acquire a branded oncology product, Odomzo, from Novartis.  The agreement was signed between subsidiaries of both the companies and is slated to close following anti-trust clearance and further ...

The Dollar Business Bureau  Indian multinational Sun Pharmaceutical Industries Ltd. said on Friday that it has concluded the acquisition of Ocular Technologies Sarl (OTS), a US-based specialist in eye care. “All the necessary formalities for closure of the said transaction have been concluded and the company has successfully completed the acquisition of Ocular Technologies Sarl, on December 15, 2016,” Sun Pharma said in a filing with the Bombay Stock Exchange (BSE). In October 2016, Sun Pharma announced the acquisition of 100% equity share in OTS, which was owned by a private equity company - Auven Therapeutics, for $40 million front payment. The Indian MNC will pay further contingent after meeting the drug development and sales milestones and also tiered royalty on sales of the ...

The Dollar Business Bureau Indian MNC Sun Pharmaceuticals Industries Ltd and Israeli biotechnology company Moebius Medical have signed an exclusive international licensing agreement to further develop MM-II, a novel pharma candidate used in the treatment of osteoarthritis pain. “Sun Pharma and Israel-based Moebius Medical have entered into an exclusive worldwide licensing deal to further develop MM-II, a novel pharmaceutical candidate for the treatment of pain in osteoarthritis,” Sun Pharma said in a BSE filing. Commenting on the deal, Kirti Ganorkar, Global Head of Business Development, Sun Pharmaceuticals, said that the deal with Moebius Medical is a part of the company’s effort to create a branded product pipeline and improve the worldwide portfolio in pain medicines. We are motivated to further develop MM-II and are hoping to come up with new innovative treatments for patients suffering ...

The Dollar Business Bureau Sun Pharmaceutical Industries Ltd. on Thursday announced it has signed a licensing agreement worth $50 million with Almirall to develop and commercialise tildrakizumab for psoriasis in Europe. As part of the agreement, the Spanish firm Almirall will pay an initial payment of $50 million. "Phase-3 studies of tildrakizumab have recently been completed. Sun Pharma will be eligible to receive development and regulatory milestone payments and, additionally, sales milestone payments and royalties on net sales, the terms of which are confidential," Indian drug major said in a statement. Psoriasis is a chronic skin disease, affecting an estimated 7.5 million people in the US alone and about 125 million people across the world. Sun Pharma said Almirall will be able to participate ...

The Dollar Business Bureau Three Indian companies, Aurobindo Pharma, Glenmark and Sun Pharma, have got the approval from the USFDA (United States Food and Drug Administration) to sell the generic versions of the famous drug Crestor prescribed for cholesterol, in the US market.  The nod, given by the US health regulator to these three domestic companies, is for the generic rosuvastatin calcium tablets in 5 mg, 10 mg, 20 mg and 40 mg strengths.  “We are one of the first ANDA (Abbreviated New Drug Application) applicants to file a significantly complete application with a paragraph IV certification. Hence, we are eligible for six months shared exclusivity of the generic drug. The drug is launched in the American market,” Aurobindo ...

The Dollar Business Bureau Sun Pharmaceutical on Monday announced that it is planning to sell its two oral solid dosage manufacturing plants to Frontida BioPharm Inc in the United States. “Frontida has agreed to continue manufacturing certain products for Sun Pharma at these facilities on a contract basis for a predetermined period. It has also agreed to offer employment to all production, quality and administrative personnel at the sites,” Gurgaon-based pharma company said in a statement. “The effect of this deal on Sun Pharmaceutical’s overall financials and activities is not material,” it added. The drug major also stated it was aware about ensuring the continued supply of quality products to patients during the divestment process. This is the second divestment ...

The Dollar Business Bureau India’s largest drug maker, Sun Pharma, received summons over pricing and marketing of generic drugs from the US Department of Justice on Saturday. The subpoena surfaced amidst the probe initiated by US regulators into the matter of price rise of generic drugs over the past few years. However, the pharma major stated that the move will not affect the company adversely. The antitrust division of the court had asked the US arm of Sun Pharma to submit documents disclosing its employee and corporate records and communication with its competitors. Besides Sun Pharma, Dr. Reddy’s Lab, Allegran Plc also received summons from the US regulators in the past seeking pricing details. However, the details of the products involved were not disclosed. ...